Want to join the conversation?
Northcoast Research analyst Kevin Hocevar probes $SHLM on how the normal seasonality will be more than offset by additional synergies and cost savings. CEO Bernard Rzepka says that the company expects a solid 4Q16 resulting from all the businesses, from all the regions. $SHLM will have more traction on the synergies coming from acquisition.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.
Well this is big! I don’t know if it’s someone’s monopoly or genuine excitement, but either way, $CSX is up 23% after market closed. I heard some activist investor is going to blow big money into CSX Corp. Anyone mind explaining?